Financials
- Fiscal year
- 2025
- Turnover
- €27.1m
- Profit
- €1.6m
- Solvency
- 49.8%
Turnover▲ 86.2%
Net result
20202025
AXONE PHARMA
ActiveSummary
AXONE PHARMA has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €8.1m and a net result of €1.6m. Equity is growing by ~3.9% per year across the filed fiscal years. Its solvency ranks better than 54% of 5451 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).
Overview
Activity
Agents specialised in the wholesale of other particular products
NACE 46180Wholesale of pharmaceutical and medical goods NACE 46460
#6 company by equity in Braine-l'Alleud, Wholesale and retail trade sector2 sites
Size
€27.1mturnover 2025
- Staff
- 28.2 FTE
- Equity
- €8.1m
- Profit
- €1.6m
Structure
- Parent
- FEBELCO · 99.9%
- Board
- 1 member
Accounts 56 d early1 of 12 deeds read
Why 96+ Founded in 2010+ Liquidity: current ratio 2.08, cash €2.7m+ Size: turnover €27.1m, 28.2 FTE, total assets €16.2m+ Profit of €1.6m (FY 2025)Show the evidence
Checked score
Score 2025
96
/ 100
Excellent
Probability in this band: under 0.55%
Better than 69% of its sector peers (NACE 46, small)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Strong
Solvency
75-20
equity 49.8% of total assets
Liquidity
48-8
short-term debt 46.7% · cash 16.9%
Profitability
73+5
return on assets 9.9%
Bankruptcy probability, 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 16 months
07-2025: < 0.1%
08-2025: < 0.1%● 0.0% vs 07-2025
09-2025: < 0.1%● 0.0% vs 08-2025
10-2025: < 0.1%● 0.0% vs 09-2025
11-2025: < 0.1%● 0.0% vs 10-2025
12-2025: < 0.1%● 0.0% vs 11-2025
01-2026: < 0.1%● 0.0% vs 12-2025
02-2026: < 0.1%▼ -4.4% vs 01-2026lowest value
03-2026: < 0.1%● 0.0% vs 02-2026lowest value
04-2026: < 0.1%● 0.0% vs 03-2026lowest value
05-2026: < 0.1%▲ +2.3% vs 04-2026
06-2026: < 0.1%▼ -2.3% vs 05-2026lowest value
07-2026: < 0.1%▲ +9.3% vs 06-2026highest value
08-2026: < 0.1%● 0.0% vs 07-2026highest value
09-2026: < 0.1%● 0.0% vs 08-2026highest value
10-2026: < 0.1%▼ -4.3% vs 09-2026
- Founded in 2010 lowers the probability for this profile
- Liquidity: current ratio 2.08, cash €2.7m lowers the probability
- Size: turnover €27.1m, 28.2 FTE, total assets €16.2m lowers the probability for this profile
- Profit of €1.6m (FY 2025) lowers the probability
Credit up to €750,000 at 30 days acceptable
Liquidity ample (current ratio 2.08 against 3.57 in 2024; short-term debt: 46.7% and cash: 16.9% of total assets), but 50.2% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, small). Better than this share of them on solvency 58%, liquidity 58%, profitability 66%, growth against the median 92%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 05-06-2026, 56 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
56 d early
2024
35 d early
2023
23 d early
2022
33 d early
2021
31 d early
2020
45 d early
2019
65 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 41 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 28 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Resignation: SRL ALEXO (director)Appointment: SRL KST Pharma (director)…
- Annual accounts filedfiscal year 2025 · full…
- Annual accounts filedfiscal year 2024 · full…
Key points
- Positive: Turnover rose in 2025from €14.5m to €27.1m ▲ 86.2% View
- Caution: Board changedlatest change 05-08-2026 · 1 in office 1 joined · 1 left View
- Positive: Among the best 14% on net resultsector median €115,462 · 5,397 companies €1.6m View
- Controlled by FEBELCOultimately: PHARMACIE BIA 99.9% View
- Positive: Always filed on timeaccounts within the deadline every year 7 years View
- Positive: 6 profitable years in a rowprofit 2025: €1.6m 6 years View
By topic
Board & ownership
- Board
- 1 member
- Parent
- FEBELCO · 99.9%
Go to Board & ownership
Network & group
- Group
- PHARMACIE BIA
Timeline
- Events
- 13
- Since
- 2017
- Next accounts
- by 31-07-2027
- 05-08-2026Resignation: SRL ALEXO (director)
- 05-06-2026Annual accounts filed
- 26-06-2025Annual accounts filed
Company details
- Sites
- 2
- Legal form
- Public limited company
- Activity
- Agents specialised in the wholesale of other particular…NACE 46180
- Founded
- 22-10-2010
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check Which other companies belong to the same group?PHARMACIE BIA · 40 companies
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.